Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 115 points (0.7%) at 16,388 as of Friday, Feb. 28, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,987 issues advancing vs. 938 declining with 158 unchanged. The Drugs industry currently sits down 0.5% versus the S&P 500, which is up 0.6%. On the negative front, top decliners within the industry include Questcor Pharmaceuticals ( QCOR), down 7.8%, Isis Pharmaceuticals ( ISIS), down 5.0%, Intercept Pharmaceuticals ( ICPT), down 3.5%, Shire ( SHPG), down 2.5% and Illumina ( ILMN), down 1.6%. Top gainers within the industry include Grifols ( GRFS), up 2.8%, Amgen ( AMGN), up 2.4%, Teva Pharmaceutical Industries ( TEVA), up 1.9%, Sanofi ( SNY), up 0.9% and Novo Nordisk A/S ( NVO), up 0.9%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Jazz Pharmaceuticals ( JAZZ) is one of the companies pushing the Drugs industry lower today. As of noon trading, Jazz Pharmaceuticals is down $7.27 (-4.4%) to $159.35 on average volume. Thus far, 726,408 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 985,400 shares. The stock has ranged in price between $159.29-$166.00 after having opened the day at $165.94 as compared to the previous trading day's close of $166.62. Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. Jazz Pharmaceuticals has a market cap of $9.4 billion and is part of the health care sector. Shares are up 31.6% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Jazz Pharmaceuticals Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.